Cargando…
The Elabela-APJ axis: a promising therapeutic target for heart failure
Heart failure (HF) is a growing epidemic with high morbidity and mortality at an international scale. The apelin–APJ receptor pathway has been implicated in HF, making it a promising therapeutic target. APJ has been shown to be activated by a novel endogenous peptide ligand known as Elabela (ELA, al...
Autores principales: | Ma, Zheng, Song, Juan-Juan, Martin, Sara, Yang, Xin-Chun, Zhong, Jiu-Chang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168569/ https://www.ncbi.nlm.nih.gov/pubmed/32314083 http://dx.doi.org/10.1007/s10741-020-09957-5 |
Ejemplares similares
-
Apelin/Elabela-APJ: a novel therapeutic target in the cardiovascular system
por: Liu, Wei, et al.
Publicado: (2020) -
ELABELA/APJ Axis Prevents Diabetic Glomerular Endothelial Injury by Regulating AMPK/NLRP3 Pathway
por: Chen, Zhida, et al.
Publicado: (2023) -
Apelin, APJ, and ELABELA: Role in Placental Function, Pregnancy, and Foetal Development—An Overview
por: Dawid, Monika, et al.
Publicado: (2021) -
APJ as Promising Therapeutic Target of Peptide Analogues in Myocardial Infarction- and Hypertension-Induced Heart Failure
por: Rossin, Daniela, et al.
Publicado: (2023) -
Lower Plasma Elabela Levels in Hypertensive Patients With Heart Failure Predict the Occurrence of Major Adverse Cardiac Events: A Preliminary Study
por: Ma, Zheng, et al.
Publicado: (2021)